Common docking domain mutation e322k of the erk2 gene is infrequent in oral squamous cell carcinomas

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 12, 2012, Pages 6155-6157

  Valiathan, Gopalakrishnan Mohan ^a   Thenumgal, Siji Jacob ^b   Jayaraman, Bhaskar ^a   Palaniyandi, Arunmozhi ^b   Ramkumar, Hemalatha ^c   Jayakumar, Keerthivasan ^a   Bhaskaran, Sajeev ^d   Ramanathan, Arvind ^a  

^a BHARATH UNIVERSITY   (India)

^b ANNAMALAI UNIVERSITY   (India)

^c SRM UNIVERSITY   (India)

^d Vananchal Dental College and Hospital   (India)

Author keywords

ERK2; ERK2 mutation; ERK2 mutation in oral cancer; Oral cancer; Oral squamous cell carcinoma

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1;

GENETICS; HUMAN; METABOLISM; MOUTH TUMOR; MUTATION; PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MOUTH NEOPLASMS; MUTATION; PHOSPHORYLATION;

EID: 84877024092     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.12.6155     Document Type: Article

References (25)

1. Arvind R, Shimamoto H, Momose F, et al (2005). A mutation in the common docking domain of ERK2 in a human cancer cell line, which was associated with its constitutive phosphorylation. Int J Oncol, 27, 1499-504.
2. Chappell WH, Steelman LS, Long JM, et al (2011). Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget, 2, 135-64.
3. Chu Y, Solski PA, Khosravi-Far R, Der CJ, Kelly K (1996). The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem, 271, 6497-501.
4. Falchook GS, Lewis KD, Infante JR, et al (2012). Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol, 13, 782-9.
5. Friday BB, Adjei AA (2008). Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res, 14, 342-6.
6. Gaestel M (2008). Specificity of signaling from MAPKs to MAPKAPKs: kinases' tango Nuevo. Front Biosci, 13, 6050-9.
7. Greulich H, Chen T-H, Feng W, et al (2005). Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants. PLoS Med, 2, 313.
8. Hsieh CH, Chang JW, Hsieh JJ (2011). Epidermal growth factor receptor mutations in patients with oral cavity cancer in a betel nut chewing-prevalent area. Head Neck, 33, 1758-64.
9. Keyse SM (2008). Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev, 27, 253-61.
10. Laimer K, Spizzo G, Gastl G, et al (2007). High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol, 43, 193-8.
11. Mahalingam M, Arvind R, Ida H, et al (2008). ERK2 CD domain mutation from a human cancer cell line enhanced anchorage-independent cell growth and abnormality in Drosophila. Oncol Rep, 20, 957-62.
12. McCubrey JA, Steelman LS, Chappell WH, et al (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta, 1773, 1263-84.
13. Mitra RS, Zhang Z, Henson BS, et al (2003). Rap1A and rap1B ras-family proteins are prominently expressed in the nucleus of squamous carcinomas: nuclear translocation of GTP-bound active form. Oncogene, 22, 6243-56.
14. Montagut C, Settleman J (2009). Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett, 283, 125-34.
15. Murugan AK, Munirajan AK, Tsuchida N (2012). Ras oncogenes in oral cancer: the past 20 years. Oral Oncol, 48, 383-92.
16. Plyte S, Majolini MB, Pacini S, et al (2000). Constitutive activation of the Ras/MAP kinase pathway and enhanced TCR signaling by targeting the Shc adaptor to membrane rafts. Oncogene, 19, 1529-37.
17. Roberts PJ, Der CJ (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 26, 3291-310.
18. Schreck R, Rapp UR (2006). Raf kinases: oncogenesis and drug discovery. Int J Cancer, 119, 2261-71.
19. Severino P, Alvares AM, Michaluart P Jr (2008). Global gene expression profiling of oral cavity cancers suggests molecular heterogeneity within anatomic subsites. BMC Res Notes, 1, 113.
20. Steelman LS, Franklin RA, Abrams SL, et al (2011). Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia, 25, 1080-94.
21. Szabó B, Nelhubel GA, Kárpáti A, et al (2011). Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral Oncol, 47, 487-96.
22. Tanoue T, Adachi M, Moriguchi T, Nishida E (2000). A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat Cell Biol, 2, 110-6.
23. Van Damme N, Deron P, Van Roy N (2010). Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer, 11, 189.
24. Wang YS, Wang YH, Xia HP, et al (2012). MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pac J Cancer Prev, 13, 255-60.
25. Yoon S, Seger R (2006). The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors, 24, 21-44.